|本期目录/Table of Contents|

[1]董文韬,陈侃,李善高,等.纳米羟基磷灰石诱导的体外特异性抗肿瘤免疫反应研究[J].浙江理工大学学报,2017,37-38(自科5):727-736.
　DONG Wentao,CHEN Kan,LI Shangao,et al.Study on In Vitro Specificity Anticancer Immune Response Induced by Nanometer Hydroxyapatite[J].Journal of Zhejiang Sci-Tech University,2017,37-38(自科5):727-736.
点击复制

纳米羟基磷灰石诱导的体外特异性抗肿瘤免疫反应研究()
分享到：

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
第37-38卷
期数:
2017年自科5期
页码:
727-736
栏目:
出版日期:
2017-08-30

文章信息/Info

Title:
Study on In Vitro Specificity Anticancer Immune Response Induced by Nanometer Hydroxyapatite
文章编号:
1673-3851 (2017) 05-0727-10
作者:
董文韬; 陈侃; 李善高; 何欢; 江国华; 孔祥东
1.浙江理工大学，a.生命科学学院;b.材料与纺织学院，杭州 310018；2.浙江中医药大学附属第一医院，杭州 310053
Author(s):
DONG Wentao;  CHEN Kan;  LI Shangao;  HE Huan;  JIANG Guohua;  KONG Xiangdong
1a.College of Life Sciences; 1b.College of Materials and Textile, Zhejiang Sci-Tech University, Hangzhou 310018, China; 2.The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou 310053, China
关键词:
纳米羟基磷灰石; 树突状细胞; 肿瘤裂解蛋白; 肿瘤免疫治疗
分类号:
Q279
文献标志码:
A
摘要:
探讨了纳米羟基磷灰石（hydroxyapatite，HAp）作为肿瘤免疫治疗佐剂或抗原载体的可行性。利用水热法合成棒状、长径200～300 nm、短径30～50 nm的纳米HAp，体外降解实验表明HAp 90 d的降解率可达30%。以人乳腺癌细胞裂解蛋白为肿瘤抗原，利用HAp负载该肿瘤抗原并刺激人外周血单个核细胞来源的树突细胞，将刺激后的树突细胞与同源淋巴细胞共培养，分离共培养后的同源淋巴细胞，并检测其对人非小细胞肺癌细胞A549、人肝癌细胞Huh7、人乳腺癌细胞MCF7、人乳腺正常细胞（Hs578Bst）的生长抑制效果。结果表明：所制备的纳米HAp无纳米毒性且生物相容性良好；HAp可显著增强人树突细胞对肿瘤抗原的吞噬作用，同时诱导同源淋巴细胞产生显著的抗原特异性免疫反应，杀伤率可达40%以上。

参考文献/References:

［1］ MCNUTT M. Cancer immunotherapy［J］. Science,2013,342(6165):1432-1433.
［2］ TAKAYAMA T, SEKINE T, MAKUUCHI M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial［J］. Lancet,2000,356(9232):802-807.
［3］ VERMORKEN J B, CLAESSEN A M, VAN TINTEREN H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial［J］. Lancet,1999,353(9150):345-350.
［4］ HANNA M G, HOOVER H C, VERMORKEN J B, et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: First randomized phase iii trials show promise［J］. Vaccine,2001,19(19):2576-2582.
［5］ ROSENBERG S A. Progress in human tumour immunology and immunotherapy［J］. Nature,2001,411(6835):380-384.
［6］ SCHIRRMACHER V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory［J］. Cancer Immunol Immunother,2005,54(6):587-598.
［7］ MATSUMOTO S, SAITO H, TSUJITANI S, et al. Allogeneic gastric cancer celldendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8+ T cells［J］. Cancer Immunol Immunother,2006,55(2):131-139.［8］ KAWAHARA M, TAKAKU H. A tumor lysate is an effective vaccine antigen for the stimulation of cd4(+) Tcell function and subsequent induction of antitumor immunity mediated by CD8+ T cells［J］. Cancer Biology Therapy,2015,16(11):1616-1625.
［9］ ROSES R E, DATTA J, CZERNIECKI B J. Radiation as immunomodulator: Implications for dendritic cellbased immunotherapy［J］. Radiation Research,2014,182(2):211-218.
［10］ PALMER D H, MIDGLEY R S, MIRZA N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma［J］. Hepatology,2009,49(1):124-132.

备注/Memo

备注/Memo:
收稿日期： 2016-10-28
网络出版日期： 2017-08-07
基金项目： 国家自然科学基金项目(51672250，51272236)；浙江理工大学521人才培养计划资助项目(1610032521302）
作者简介： 董文韬(1990-)，男，山东烟台人，硕士研究生，主要从事生物材料用于肿瘤治疗交叉科学方面的研究
通信作者： 孔祥东，kongxiangdong@gmail.com
更新日期/Last Update: 2017-09-26